Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment of Patients With Nocturia

This study has been completed.
Information provided by (Responsible Party):
Serenity Pharmaceuticals, Inc. Identifier:
First received: July 9, 2009
Last updated: April 24, 2014
Last verified: April 2014
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.

Condition Intervention Phase
Drug: SER120
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia

Further study details as provided by Serenity Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • number of nocturic episodes [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • proportion of nights with less than or equal to one nocturic episode [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Enrollment: 301
Study Start Date: June 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SER120
Drug: SER120
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female 50 years or older
  • Nocturia of 6 or more months duration averaging 2 episodes or more per night

Exclusion Criteria:

  • CHF
  • Diabetes
  • Diabetes Insipidus
  • Renal Insufficiency
  • Hepatic Insufficiency
  • Incontinence
  • Illness requiring steroids
  • Current or past urologic malignancy
  • Nephrotic Syndrome
  • Unexplained pelvic masses
  • Urinary bladder neurological dysfunction
  • Urinary bladder surgery or radiotherapy
  • Sleep Apnea
  • Pregnant or breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00937859

United States, North Carolina
Piedmont Medical Research Assoc.
Winston-Salem, North Carolina, United States, 27103
Sponsors and Collaborators
Serenity Pharmaceuticals, Inc.
  More Information

Responsible Party: Serenity Pharmaceuticals, Inc. Identifier: NCT00937859     History of Changes
Other Study ID Numbers: SPC-SER120-DB1-200901 
Study First Received: July 9, 2009
Last Updated: April 24, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms processed this record on October 27, 2016